NAD+ Precursors Compared: NR vs NMN for Longevity (UK)

NR and NMN both raise NAD+ levels in humans, but the evidence does not clearly favour one over the other. NR has a larger history of manufacturer-funded safety trials; NMN has more rodent longevity data and consumer market presence. For evidences, product quality, purity, stable salt form and honest labelling matter far more than the precursor name on the bottle.

1. What Are NR and NMN?

Both compounds are derivatives of vitamin B3 (niacin) and feed into the NAD+ biosynthetic pathway:

• NR (nicotinamide riboside) is a nucleoside. It is converted inside cells to NMN, then to NAD+.
• NMN (nicotinamide mononucleotide) is a nucleotide. It is one step closer to NAD+ and requires conversion by the enzyme NMNAT.

For years it was debated whether NMN could be absorbed intact from the gut or whether it had to be converted to NR first. More recent work suggests specific transporters can move NMN into cells in some tissues, but the practical implication for oral supplementation remains unclear.

2. Bioavailability and Pharmacokinetics

Both NR and NMN raise blood NAD+ levels within hours to days. NR has been studied extensively using the NIAGEN ingredient (ChromaDex), with trials showing dose-dependent NAD+ increases and a reasonable safety profile. NMN pharmacokinetic studies have expanded rapidly since 2020, showing that oral NMN at 250–900 mg/day reliably elevates NAD+ metabolites.

Head-to-head human bioavailability studies comparing the same molar dose are limited. Claims that NMN is "more direct" or that NR "does not work" are marketing simplifications, not established scientific conclusions.

3. Clinical Evidence: What Do Human Trials Say?

NR trials

• Martens et al. (2018): NR at 1,000 mg/day for 6 weeks safely raised NAD+ in older adults.
• Dellinger et al. (2017): doses up to 2,000 mg/day for 8 weeks were well tolerated.
• Cardiovascular markers: some trials report improvements in blood pressure and arterial stiffness, though results are mixed.

NMN trials

• Igarashi et al. (2022): NMN at 250 mg/day improved walking speed and grip strength in healthy older men.
• Yoshino et al. (2021): NMN improved muscle insulin sensitivity in women with prediabetes.
• Katayoshi et al. (2022): NMN improved arterial stiffness when combined with exercise.

No human trial has compared NR and NMN for lifespan, and no trial has measured mortality for either compound.

4. Side-by-Side Comparison

5. Safety Summary

Both NR and NMN are generally well tolerated at the doses used in published trials. Common side effects include mild nausea, flushing, headache and fatigue. Serious adverse events are rare in short-term studies.

Cautions:

• Long-term safety data beyond 1–2 years are not available.
• Theoretical concern that raising NAD+ could fuel certain cancers, though no human evidence exists.
• People with liver or kidney disease, pregnant or breastfeeding women, and those on medication should seek medical advice first.

6. Buying NAD+ Precursors locally

• Purity certificate: compare third-party testing, not just a brand claim.
• Stable form: NMN-HCl and other salt forms degrade more slowly than free-acid NMN.
• seller:-registered business with a working address and returns policy.
• No disease claims: avoid any product that claims to treat, cure or reverse ageing. Such claims are unauthorised.

7. References

These sources are referenced inline throughout the article and listed below for full transparency.

8. FAQ

10. Medical Disclaimer

The content on this site is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting any supplement, especially if you are pregnant, nursing, taking medication or have a medical condition.